Merck
Merck inks $493M biobucks deal to use Cyprumed’s tech to create oral peptides
Cyprumed, Merck, biobucks, Peptides
The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring
Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.
Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal
Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement
Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug
Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme
Corrected: Merck opens billion-dollar US facility to make Gardasil
Merck, Gardasil, Facility (object), Vaccines, Merck ‘s, United States
Merck opens $1B Gardasil manufacturing facility in North Carolina
Merck, Facility (object), Manufacture, Durham, North Carolina
Merck Opens $1 Billion Vaccine Manufacturing Facility in North Carolina
Merck, vaccine manufacturing, Durham, North Carolina, Gardasil, HPV vaccine, pharmaceutical industry, US manufacturing
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda